奥门丁-1通过减弱局部炎症来抑制良性前列腺增生的发展
Yi-Yi Wang1,2,3, Guo-Qiang Zhu1,2,3, Kun Xia4
1Department of Orthopedics, Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Molecular medicine (Cambridge, Mass.)
|March 23, 2024
概括
在良性前列腺增生 (BPH) 模型中,INTELECTIN-1 (ITLN-1) 降低了炎症和前列腺扩大. 这种抗炎蛋白通过向局部前列腺炎症来治疗BPH的治疗潜力.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 炎症研究 炎症研究
- 分子生物学分子生物学
背景情况:
- 良性前列腺增生 (BPH) 在老年男性中很常见,慢性炎症是关键因素.
- 奥门丁-1 (Omentin-1),也称为智能丁-1 (ITLN-1),是一种抗炎蛋白.
- 这项研究探讨了ITLN-1通过调节前列腺炎症来缓解BPH的作用.
研究的目的:
- 研究ITLN-1在良性前列腺增生 (BPH) 的治疗潜力.
- 为了确定ITLN-1是否可以减少与BPH发展相关的炎症.
主要方法:
- 在体内研究中利用ITLN-1淘汰和腺病毒介导的过度表达小鼠模型.
- 通过前列腺体重指数和组织学分析评估BPH严重程度.
- 在实验室中评估ITLN-1对前列腺上皮细胞增殖和巨细胞炎症反应的影响.
主要成果:
- 缺少ITLN-1会加剧BPH指标,包括前列腺体重增加和TNF-α水平.
- 在BPH模型中,ITLN-1过度表达减少了前列腺重量,光膜面积和TNF-α.
- 在体外,ITLN-1抑制了前列腺上皮细胞的增殖和巨细胞TNF-α的产生.
结论:
- 通过减少局部前列腺炎症,ITLN-1显著抑制BPH的发展.
- ITLN-1 显示出作为治疗治疗良性前列腺增生症的治疗标的潜力.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
159
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
159
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


